Product Description
Basimglurant is a highly promising antidepressant drug now in clinical development for depression. a novel negative allosteric modulator of metabotropic glutamate receptor 5 (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26219727/)
Mechanisms of Action: MGLUR5 Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Neuralgia|Trigeminal Neuralgia *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Denmark, Germany, India, Israel, Italy, Poland, Spain, Turkey, United Kingdom, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Trigeminal Neuralgia
Phase 2: Tuberous Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Basimglurant in children, adolescents, and young adults with Tuberous Sclerosis Complex | P2 |
Active, not recruiting |
Tuberous Sclerosis |
2026-09-21 |
|
| NOE-TSC-201 | P2 |
Not yet recruiting |
Tuberous Sclerosis |
2025-08-08 |
|
| A Phase II/III efficacy and safety study of basimglurant in patients with trigeminal neuralgia | P3 |
Active, not recruiting |
Trigeminal Neuralgia |
2025-05-05 |
|
| NOE-TGN-201 | P3 |
Recruiting |
Trigeminal Neuralgia |
2025-01-31 |